Engel, A. G., Shen, X.-M., Selcen, D. & Sine, S. M. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol. 14, 420–434 (2015).
Li, H., Teng, J. & Hibbs, R. E. Structural switch in acetylcholine receptors in developing muscle. Nature 632, 1174–1180 (2024).
Ramdas, S., Beeson, D. & Dong, Y. Y. Congenital myasthenic syndromes: increasingly complex. Curr. Opin. Neurol. 37, 493–501 (2024).
Rodríguez Cruz, P. M., Palace, J. & Beeson, D. The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes. Int. J. Mol. Sci. 19, 1677 (2018).
Shen, X.-M. et al. Mutation causing severe myasthenia reveals functional asymmetry of AChR signature cystine loops in agonist binding and gating. J. Clin. Investig. 111, 497–505 (2003).
Shen, X.-M., Brengman, J. M., Edvardson, S., Sine, S. M. & Engel, A. G. Highly fatal fast-channel syndrome caused by AChR ɛ subunit mutation at the agonist binding site. Neurology 79, 449–454 (2012).
Cetin, H., Beeson, D., Vincent, A. & Webster, R. The structure, function, and physiology of the fetal and adult acetylcholine receptor in muscle. Front. Mol. Neurosci. 13, 581097 (2020).
Engel, A. G. The therapy of congenital myasthenic syndromes. Neurotherapeutics 4, 252–257 (2007).
Engel, A. G., Ohno, K. & Sine, S. M. Sleuthing molecular targets for neurological diseases at the neuromuscular junction. Nat. Rev. Neurosci. 4, 339–352 (2003).
Lee, M., Beeson, D. & Palace, J. Therapeutic strategies for congenital myasthenic syndromes. Ann. N. Y. Acad. Sci. 1412, 129–136 (2018).
Sine, S. M. et al. Mechanistic diversity underlying fast channel congenital myasthenic syndromes. Ann. N. Y. Acad. Sci. 998, 128–137 (2003).
Rahman, M. M. & Fatema, K. Fast channel congenital myesthenic syndrome: reporting two cases with mutation of CHRNE gene and short review. J. Pediatric Neurosci. 17, 160–163 (2022).
Mallappa, A., Tirupathi, S., Boyd, J., B’Connor, O. & Illingworth, M. 661 Fast channel syndrome: presentation, diagnosis and management in an infant. Pediatr. Res. 68, 338–338 (2010).
Palace, J. et al. Clinical features in a series of fast channel congenital myasthenia syndrome. Neuromuscul. Disord. 22, 112–117 (2012).
Palace, J., Wiles, C. M. & Newsom-Davis, J. 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. J. Neurol. Neurosurg. Psychiatry 54, 1069 (1991).
Kao, J. C. et al. Congenital myasthenic syndromes in adult neurology clinic. Neurology 91, e1770–e1777 (2018).
Dowling, J. J., D. Gonorazky, H., Cohn, R. D. & Campbell, C. Treating pediatric neuromuscular disorders: the future is now. Am. J. Med. Genet. Part A 176, 804–841 (2018).
Li, A. et al. Structures of the human adult muscle-type nicotinic receptor in resting and desensitized states. Cell Rep. 44, 5115581 (2025).
Bertrand, D. & Gopalakrishnan, M. Allosteric modulation of nicotinic acetylcholine receptors. Biochem. Pharmacol. 74, 1155–1163 (2007).
Engel, A. G. et al. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann. Neurol. 11, 553–569 (1982).
Fukudome, T., Ohno, K., Brengman, J. M. & Engel, A. G. Quinidine normalizes the open duration of slow-channel mutants of the acetylcholine receptor. NeuroReport 9, 1907–1911 (1998).
Fukudome, T., Ohno, K., Brengman, J. M. & Engel, A. G. AChR channel blockade by quinidine sulfate reduces channel open duration in the slow-channel congenital myasthenic syndrome. Ann. N. Y. Acad. Sci. 841, 199–202 (1998).
Harper, C. M., Fukodome, T. & Engel, A. G. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 60, 1710–1713 (2003).
García-Colunga, J., Awad, J. N. & Miledi, R. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc. Natl Acad. Sci. USA 94, 2041–2044 (1997).
Schara, U. & Lochmüller, H. Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics 5, 542–547 (2008).
Chaouch, A. et al. A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome. J. Neurol. 259, 474–481 (2012).
Nayak, T. K. et al. Functional differences between neurotransmitter binding sites of muscle acetylcholine receptors. Proc. Natl Acad. Sci. USA 111, 17660–17665 (2014).
Zarkadas, E. et al. Conformational transitions and ligand-binding to a muscle-type nicotinic acetylcholine receptor. Neuron 110, 1358–1370 (2022).
Kediha, M. I., Tazir, M., Sternberg, D., Eymard, B. & Ali Pacha, L. Congenital myasthenic syndromes by Epsilon subunit mutations: phenotypic profiles of 17 Algerian families. Rev. Neurol. 181, 79–84 (2025).
Li, H. et al. Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures. Cell 188, 2390–2406 (2025).
Beeson, D. & Newsom-Davis, J. in Channelopathies (eds Lehmann-Horn, F. & Jurkat-Rott, K.) 85–114 (Elsevier Science, 2000).
Wang, J. & Lindstrom, J. Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors. Br. J. Pharmacol. 175, 1805–1821 (2018).
Burke, S. M. et al. Structural mechanisms of α7 nicotinic receptor allosteric modulation and activation. Cell 187, 1160–1176 (2024).
Saito, A., Matsui, S., Chino, A., Sato, S. & Takeshita, N. Discovery and pharmacological characterization of novel positive allosteric modulators acting on skeletal muscle-type nicotinic acetylcholine receptors. Biochem. Biophys. Res. Commun. 668, 27–34 (2023).
Ohno, K. et al. Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor ε subunit. Neuron 17, 157–170 (1996).
Wang, H.-L. et al. Acetylcholine receptor M3 domain: stereochemical and volume contributions to channel gating. Nat. Neurosci. 2, 226–233 (1999).
Sine, S. M. et al. Naturally occurring mutations at the acetylcholine receptor binding site independently alter ACh binding and channel gating. J. Gen. Physiol. 120, 483–496 (2002).
Shen, X.-M., Brengman, J. M., Sine, S. M. & Engel, A. G. Myasthenic syndrome AChRα C-loop mutant disrupts initiation of channel gating. J. Clin. Investig. 122, 2613–2621 (2012).
Dejthevaporn, C. et al. Treatment of slow-channel congenital myasthenic syndrome in a Thai family with fluoxetine. J. Clin. Neurosci. 96, 85–89 (2022).
Gisselmann, G., Alisch, D., Welbers-Joop, B. & Hatt, H. Effects of quinine, quinidine and chloroquine on human muscle nicotinic acetylcholine receptors. Front. Pharmacol. 9, 1339 (2018).
Engel, A. G. et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum. Mol. Genet. 5, 1217–1227 (1996).
Shen, X.-M. et al. Mutations causing slow-channel myasthenia reveal that a valine ring in the channel pore of muscle AChR is optimized for stabilizing channel gating. Hum. Mutat. 37, 1051–1059 (2016).
Arias, H. R., Feuerbach, D., Bhumireddy, P. & Ortells, M. O. Inhibitory mechanisms and binding site location for serotonin selective reuptake inhibitors on nicotinic acetylcholine receptors. Int. J. Biochem. Cell Biol. 42, 712–724 (2010).
Arias, H. R., Bhumireddy, P. & Bouzat, C. Molecular mechanisms and binding site locations for noncompetitive antagonists of nicotinic acetylcholine receptors. Int. J. Biochem. Cell Biol. 38, 1254–1276 (2006).
Roden, D. M., Woosley, R. L. & Primm, R. K. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am. Heart J. 111, 1088–1093 (1986).
Whittington, C. J., Kendall, T. & Pilling, S. Are the SSRIs and atypical antidepressants safe and effective for children and adolescents? Curr. Opin. Psychiatry 18, 21–25 (2005).
Montgomery, S., Ferguson, J. M. & Schwartz, G. E. The antidepressant efficacy of reboxetine in patients with severe depression. J. Clin. Psychopharmacol. 23, 45–50 (2003).
Andreoli, V., Caillard, V., Deo, R. S., Rybakowski, J. K. & Versiani, M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J. Clin. Psychopharmacol. 22, 393–399 (2002).
Arias, H. R., Ortells, M. O. & Feuerbach, D. (−)-Reboxetine inhibits muscle nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites. Neurochem. Int. 63, 423–431 (2013).
Ohno, K. et al. Congenital myasthenic syndrome caused by prolonged acetylcholine receptor channel openings due to a mutation in the M2 domain of the epsilon subunit. Proc. Natl Acad. Sci. USA 92, 758–762 (1995).
Milone, M. et al. Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor α subunit. J. Neurosci. 17, 5651 (1997).
Dwyer, T. M., Adams, D. J. & Hille, B. The permeability of the endplate channel to organic cations in frog muscle. J. Gen. Physiol. 75, 469–492 (1980).
Sine, S. M. End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease. Physiol. Rev. 92, 1189–1234 (2012).
Nicole, S. et al. Congenital myasthenic syndromes or inherited disorders of neuromuscular transmission: recent discoveries and open questions. J. Neuromuscul. Dis. 4, 269–284 (2017).
Pham, M. C. et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 146, 319–336 (2023).
Deflorio, C., Catalano, M., Fucile, S., Limatola, C. & Grassi, F. Fluoxetine prevents acetylcholine-induced excitotoxicity blocking human endplate acetylcholine receptor. Muscle Nerve 49, 90–97 (2014).
Zhou, S. et al. Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Sleep 46, zsad177 (2023).
Tanum, L. Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr. Scand. 101, 37–40 (2000).
Rahman, M. M. et al. Structural mechanism of muscle nicotinic receptor desensitization and block by curare. Nat. Struct. Mol. Biol. 29, 386–394 (2022).
Thompson, M. J., Mansoub Bekarkhanechi, F., Ananchenko, A., Nury, H. & Baenziger, J. E. A release of local subunit conformational heterogeneity underlies gating in a muscle nicotinic acetylcholine receptor. Nat. Commun. 15, 1803 (2024).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
Punjani, A., Zhang, H. & Fleet, D. J. Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction. Nat. Methods 17, 1214–1221 (2020).
Kimanius, D., Dong, L., Sharov, G., Nakane, T. & Scheres, S. H. W. New tools for automated cryo-EM single-particle analysis in RELION-4.0. Biochem. J. 478, 4169–4185 (2021).
Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. Sect. D 66, 213–221 (2010).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D 60, 2126–2132 (2004).
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. Sect. D 66, 12–21 (2010).
Sanchez-Garcia, R. et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun. Biol. 4, 874 (2021).
Smart, O. S., Neduvelil, J. G., Wang, X., Wallace, B. A. & Sansom, M. S. P. HOLE: a program for the analysis of the pore dimensions of ion channel structural models. J. Mol. Graph. 14, 354–360 (1996).
Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2021).
Pear, W. S., Nolan, G. P., Scott, M. L. & Baltimore, D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl Acad. Sci. USA 90, 8392–8396 (1993).
Sine, S. M. Molecular dissection of subunit interfaces in the acetylcholine receptor: identification of residues that determine curare selectivity. Proc. Natl Acad. Sci. USA 90, 9436–9440 (1993).
Mukhtasimova, N., daCosta, C. J. B. & Sine, S. M. Improved resolution of single channel dwell times reveals mechanisms of binding, priming, and gating in muscle AChR. J. Gen. Physiol. 148, 43–63 (2016).
Colquhoun, D. & Sigworth, F. J. in Single-Channel Recording (eds Sakmann, B. & Neher, E.) 191–263 (Springer, 1983).
Sigworth, F. J. & Sine, S. M. Data transformations for improved display and fitting of single-channel dwell time histograms. Biophys. J. 52, 1047–1054 (1987).
